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Abstract
Background:  We wished to evaluate the clinical response following ATP-Tumor
Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with
advanced ovarian cancer. The results are compared with that of a similar assay used in a different
country in terms of evaluability and clinical endpoints.
Methods: From November 1998 to November 2001, 46 patients with pre-treated, advanced
ovarian cancer were given a total of 56 courses of chemotherapy based on in-vitro ATP-TCA
responses obtained from fresh tumor samples or ascites. Forty-four patients were evaluable for
results. Of these, 18 patients had clinically platinum resistant disease (relapse < 6 months after first
course of chemotherapy). There was evidence of cisplatin resistance in 31 patients from their first
ATP-TCA. Response to treatment was assessed by radiology, clinical assessment and tumor
marker level (CA 125).
Results: The overall response rate was 59% (33/56) per course of chemotherapy, including 12
complete responses, 21 partial responses, 6 with stable disease, and 15 with progressive disease.
Two patients were not evaluable for response having received just one cycle of chemotherapy: if
these were excluded the response rate is 61%. Fifteen patients are still alive. Median progression
free survival (PFS) was 6.6 months per course of chemotherapy; median overall survival (OAS) for
each patient following the start of TCA-directed therapy was 10.4 months (95% confidence interval
7.9–12.8 months).
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Conclusion: The results show similar response rates to previous studies using ATP-TCA directed
therapy in recurrent ovarian cancer. The assay shows high evaluability and this study adds weight
to the reproducibility of results from different centres.
Background
Despite surgical refinements and the introduction of land-
mark chemotherapy agents such as cisplatin in the 1970's
and paclitaxel in the 1990's, improvements in the overall
survival of epithelial ovarian cancer have only been mod-
est [1]. The currently accepted first line treatment is cis- or
carboplatin with the addition of a taxane and this is now
the most commonly employed control arm in ran-
domised trials [2,3]. This together with surgery can result
in response rates of 70–80%. However, most of these
patients will relapse between one to two years and only
20–30% will be alive after 5 years with a median overall
survival of 35 months [2,3].
The optimal treatment of recurrent disease is unclear and
a number of different drugs are used. The response rate to
second line treatment depends on the prevalence of plati-
num resistance at that time [4–7]. The length of the dis-
ease free interval categorises patients into platinum-
sensitive (those progressing 6 months or more after com-
pletion of first line platinum agents) and platinum refrac-
tory (those progressing on or within 6 months after
completion of first line platinum agents). Several different
chemotherapy agents have shown some activity in
patients with recurrent disease but response rates are still
under 30% in unselected groups [8]. However, there is
evidence of heterogeneity of chemosensitivity and
patients may benefit from a change of treatment if they
progress on the first drug selected. There are no phase III
randomized trial-based data to suggest that combination
chemotherapy is any better than single agent chemother-
apy, though recent phase II trials suggest that combina-
tions may be useful, at least in patients relapsing after
more than six months off first-line treatment [9,10].
Selection of the optimal salvage chemotherapy by a labo-
ratory test would in theory allow individualisation of
treatment. However, this requires a standardised, evalua-
ble assay technique. The ATP tumor chemosensitivity
assay (ATP-TCA) described here is a new generation assay.
Previous chemosensitivity assays have been dogged by
technical difficulties over the past 25 years [11,12],
though several have shown potential in clinical trials [13].
The ATP-TCA compares favourably with all previous
methods in terms of standardisation, evaluability, tumor
cell number required, reproducibility and accuracy. [13–
15] It is possible to test cells from needle biopsies and
malignant effusions as well as solid tumor biopsies. The
high sensitivity of the ATP-TCA requires only 1 × 106
tumor cells to test 4–6 drug regimens. Encouraging corre-
lations between assay results and clinical outcome have
been reported [16], and use of the assay in one centre
(University of Köln, Köln, Germany) for patients with
recurrent ovarian cancer produced a 64% response rate
with improved progression-free survival [17].
Here we present the results of ATP-TCA directed therapy in
multiple centres using 56 human epithelial ovarian cancer
specimens from 46 patients previously treated with chem-
otherapy, 8 of whom received multiple ATP-TCA directed
therapies. We report on the objective response rate (ORR),
progression free survival (PFS) and the overall survival
(OAS) and discuss the results in relation to similar ATP
assays carried out in different centres.
Patients and methods
Patients and treatment
From October 1998 to November 2001 forty-six patients
with histologically proven recurrent ovarian carcinoma
were treated prospectively with ATP-TCA directed chemo-
therapy regimens. Patient characteristics are summarised
in Table 1. Written informed consent was obtained from
all patients. tumor specimens were obtained either at
laparotomy, laparoscopy or paracentesis of a malignant
ascites or effusion. Specimens were placed into sterile con-
tainers containing a basic transport medium (DMEM,
Sigma-Aldrich, Poole, Dorset UK) with penicillin, strepto-
mycin and gentamicin as additives. Ascites containers also
contained heparin sulphate 5000 i.u. These were immedi-
ately packed into chilled polystyrene containers and trans-
ported by courier to arrive in the laboratory (Queen
Alexandra Hospital, Portsmouth) within 24 hours. All
specimens were confirmed for malignancy by histology or
cytology.
Patients were treated with the optimal protocol as indi-
cated by the ATP-TCA assay. This was the regimen with the
highest ex-vivo activity that could be tolerated by the
patient concerned, taking into account the likely toxicity
profile of the drugs selected. Combination therapies had
to demonstrate considerable activity over the best single
agent tested if they were to be selected. Any supportive
treatment needed was freely instituted when need arose
during therapy.
The only eligibility criteria were relapsed epithelial ovar-
ian cancer previously treated with chemotherapy and fit-
ness to receive further chemotherapy. Relapse was definedBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/19
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as occurrence of malignant pleural effusion or ascites
(substantiated by positive cytology), a CA125 of over 70
U/mL which had at least doubled from the previous value
(samples taken ≥ 28 days apart) [18] or radiographically
measurable disease with >20% increase in the sum of the
longest diameter of target lesions. Patients of any WHO
performance status thought fit enough by their oncologist
to withstand chemotherapy were included in this series,
irrespective of marrow, renal or hepatic function.
Therapy was monitored using clinical, biochemical and
radiological parameters. Where possible CA125 measure-
ments were taken before treatment and monthly thereaf-
ter in order to monitor response. Physical examination
was carried out monthly. tumor imaging was performed
routinely after 3 cycles or earlier to establish progressive
disease. Patient response to treatment was assessed by
clinical and radiological means according to RECIST crite-
ria as complete response (CR), partial response (PR), sta-
ble disease (SD) or progressive disease (PD) [19]. The
ORR was defined as the sum of CR and PR. A falling
CA125 without a clinical or radiological correlate did not
qualify a patient for a CR or PR.
Patients were regarded as evaluable if a minimum of 2
cycles of chemotherapy were administered. All chemo-
therapy was continued for a minimum of 4 cycles in
responders and in patients experiencing stable disease. All
patients were followed up routinely on a three monthly
basis with clinical examination and CA125 levels. Addi-
tional imaging was performed as indicated. On relapse of
disease, if further treatment was offered, this was either
physician's choice or a further course of ATP-TCA directed
therapy. Patients were defined as platinum-refractory if
they showed progression of disease during or within 6
months after completion of platinum-based chemother-
apy [6,20,21]
ATP chemosensitivity testing
The ATP-TCA methodology has been previously described
in detail [14,22]. Briefly, specimens were obtained at sur-
gery or from malignant effusions. tumor cells were iso-
lated by enzymatic dissociation using Collagenase Type H
(Sigma-Aldrich, Poole, Dorset, UK) at a concentration of
0.75 mg/mL for 12 hours. Cell viability was expressed as a
percentage using a counting chamber and the total viable
cell count used to calculate final working volumes. The
tumor cells were then seeded into each well of a 96-well
polypropylene microplate using 20,000 cells per well for
solid tumors and 10,000 cells per well for ascites samples.
These were tested with a maximum of 14 different single
agent and combination chemotherapy agents. Drugs were
added to the wells prior to seeding and there was no pre-
incubation period for the cells. These included standard
and experimental combinations (Table 2).
Each single agent or combination was tested at six dou-
bling dilutions (6.25% to 200%) of test drug
concentrations (TDC) derived from pharmacokinetic
data, including the degree of protein binding. The assay is
Table 1: 
PATIENT CHARACTERISTICS N = 46
Median age (range) 55 (33–76)
Median performance status (range) 2 (0–4)
Median number of prior chemotherapies (range) 2 (1–5)
Summary of prior chemotherapy
Number of treatments prior to ATP-TCA No. Patients
1 13 (28%)
2 18 (39%)
3 10 (22%)
4 4 (9%)
5 1 (2%)
FIGO stage (No.)
IIIc 40 (87%)
IV 6 (13%)
Patients with non-serous histology 6 (13%)
Platinum-refractory patients* 18 (39%)
Patients with a Cisplatin Index >350 on first ATP-TCA 33 (72%)
Patients with ascites 37 (80%)
*Defined as relapse < 6 months after completion of first course of platinum containing chemotherapyBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/19
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carried out in triplicate wells with positive and negative
controls using a serum-free medium (CAM, DCS Innova-
tive Diagnostik Systeme, Hamburg, Germany). The ATP
content of each well was measured after 6 days incubation
(5% CO2, 37°C and 100% humidity) by the addition of
luciferin-luciferase to an aliquot of the lysed cells in a
luminometer (MPLX, Berthold Diagnostic Systems, Ham-
burg, Germany) and analysed with custom software to
provide both numerical and graphical results. Lumines-
cence measurements are directly related to ATP levels and
allow measurement of the percentage inhibition by refer-
ence to untreated control wells included with each plate
[14,15].
The results are interpreted and compared using four
parameters. The drug concentrations that achieve 50 and/
or 90% growth inhibition (IC50 and IC90 respectively)
are calculated by interpolation. A sensitivity index (Index
SUM) is calculated as the sum of the percentage inhibition
at each concentration tested (SI = 600 - Σ %Inhibition at
200,100,50,25,12.5 and 6.25% TDC). Lastly, the area
under the dose-response curve (Index AUC) is calculated
using the trapezoidal rule. Previous studies have shown
the Index SUM to be superior to the Index AUC and IC50
for determination of sensitivity and resistance as this
relates more closely to the shape of the concentration-
inhibition curve [16]. Definitions of sensitivity and resist-
ance for Index SUM and Index AUC were calculated by
log-rank tests referring to PFS and OAS [14]. In this study
an Index SUM >350 was taken to indicate probable resist-
ance. Drugs were classified into three groups (probably
sensitivity, equivocal sensitivity and probable resistance)
on the basis of IndexSUM, and clear evidence of a concen-
tration-response curve with at least 95% inhibition at
100% TDC. Synergism or additive effects for individual
patients were not routinely assessed. A report was gener-
ated including the interpretation of the data, the concen-
tration-inhibition graphs and the derived parameters
(IndexSUM, IndexAUC, IC90 and IC50). This report was
sent to the oncologist in charge of the patient who decided
the treatment according to the assay results and previous
toxicity data from the patient concerned. In all cases,
patients were treated with drugs shown to be active in the
assay.
Statistics
The results of this non-comparative study are presented
with descriptive statistics based on an intention to treat
analysis. All data was collected retrospectively by scrutiny
of case notes and investigational results. Clinical details
were collected blind to the assay results. PFS and OAS
were measured from the first day of ATP-TCA directed
chemotherapy. OAS has not been corrected for cause of
death, which has been considered to be due to ovarian
cancer. Autopsies were not performed on these patients.
Descriptive statistics are used to describe patient demo-
graphic and disease characteristics. Kaplan-Meier survival
methods were used to summarize the time-to event varia-
bles of time to progression and overall survival.
Results
A total of 46 patients underwent 56 courses of ATP-TCA
directed chemotherapy. Two patients received only one
cycle of assay directed therapy and then withdrew from
treatment. Second look laparotomies were not performed,
but 9 patients had tissue samples taken at diagnostic
laparoscopy. None of the patients had further tumor
debulking surgery.
The treatments given are summarised in Table 2. Drug
combinations were given on 44 (79%) occasions and of
these 30 (54%) were non-standard protocols.
Table 2: Chemotherapy Regimens Used
Regimen Number of patient treatments
(N = 56)
Protocol
Carboplatin 1 5(GFR+25)mg;6 cycles; q3 wk
Mitoxantrone 1 12 mg/m2; q3 wk
Treosulfan 1 7000 mg/m2; q4 wk
Gemcitabine 1 1250 mg/m2; d1,8; q3 wk
Treosulfan and gemcitabine 23 5000 mg/m2; d1 & 1000 mg/m2; d1; q3 wk
Liposomal Doxorubicin (Caelyx®/Doxil®)8 4 0  m g / m 2; d1; q3 wk
Mitoxantrone and paclitaxel 8 4 mg/m2; d1,2 & 175 mg/m2; d3; q3 wk
Cisplatin and gemcitabine 5 75 mg/m2; d1 & 1250 mg/m2; d1,8; q3 wk
Mitoxantrone and gemcitabine 1 12 mg/m2; d1,21 & 1000 mg/m2; d1; q3 wk
Liposomal Doxorubicin and gemcitabine 1 45 mg/m2; d1 & 500 mg/m2; d1,8; q3 wk
Epirubicin and treosulfan 2 60 mg/m2; d1 & 5000 mg/m2; d1; q4 wk
Vinorelbine and Liposomal Doxorubicin 2 15 mg/m2 & 30 mg/m2 ; q3 wk
Epirubicin and paclitaxel 2 25 mg/m2; d1,2 & 175 mg/m2; d3; q3 wkBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/19
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Response
Of the 54 ATP-TCA directed chemotherapies evaluable for
response, there were 12 complete responses (CR), 21 par-
tial responses (PR), 6 stable disease (SD) and 15 with pro-
gressive disease (PD). Two patients were not evaluable for
response (withdrew after one cycle of treatment). Of the
44 patients treated, 15 are still alive at the date of analysis
(3 CR, 9 PR, 2 SD and 1 PD). For evaluable patients, the
ORR was 61% per course of ATP-TCA directed chemother-
apy (12 CR and 21 PR). By intention-to-treat (ITT) analy-
sis, the response rate was 59%, including the two patients
who received just one cycle of chemotherapy and were not
evaluable. The results of chemotherapy are summarised in
Table 3.
Eight patients had more than one course of ATP-TCA
directed chemotherapy (range 2–4 courses). Four of these
responded to two or more courses of ATP-TCA directed
chemotherapy. One patient responded to three successive
courses and 3 of these patients are still alive at the time of
analysis. The median OAS for these patients was 13.7
months (Anderson 95% CI 11.5–15.9 months) from the
start of ATP-TCA directed therapy.
Of the clinically platinum-resistant patients (18), there
were 3CR, 8 PR, 4 SD, 3 PD with a 61% ORR. Of plati-
num-sensitive patients (26), there were 8 CR, 9 PR, 2 SD,
7 PD with a 65% ORR. Of 54 ATP-TCAs, 52 were evalua-
ble for cisplatin sensitivity. Analysis of patients grouped
by Index SUM for cisplatin sensitivity showed 72% of
patients to be resistant to cisplatin in the assay. The ORR
of patients with a cisplatin sensitivity index >350 and
<350 was 58% (N = 38) and 75% (N = 12) respectively.
Survival
The median PFS for all 56 patients was 6.6 months
(Anderson 95% CI 3.6–9.6 months) and the median OAS
10.4 months (Anderson 95% CI 7.9–12.8 months). Fig-
ure 1 illustrates progression free survival and figure 2 illus-
trates overall survival for the group calculated by Kaplan-
Meier statistics.
Discussion
The 59% response rate (61% for evaluable patients) sup-
ports data from previous work using the ATP-TCA in
another centre [17]. All patients had stage IIIc or IV dis-
ease and the inclusive criteria for treatment (with regard to
performance status, laboratory criteria and previous toxic-
ity) allowed the inclusion of patients who were clinically
unwell as a result of their disease or otherwise. It is reason-
able to assume that the outcomes for this group are likely
to be less favourable than generally quoted figures.
The use of antineoplastic agents in third line and subse-
quent therapy has been questioned since the objective
response rate is so low in women failing previous therapy.
In the UK, most patients with relapse after second line
chemotherapy are referred for palliative care [23]. It has
also been suggested that potentially useful new agents
should not be evaluated in multiple treated patient popu-
lations as they risk being labelled "inactive" [24]. How-
ever, we know that women may survive for months and
even years after failing initial therapy and that they may
respond several more times to chemotherapy regimes,
particularly in the platinum-sensitive group [25,26]. A
recent study showed that compared to non-cancer con-
trols, women with recurrent ovarian cancer overwhelm-
ingly preferred salvage therapy to palliation. Quality of
life was of secondary importance to the desire to continue
aggressive treatment [27]. However, the choice of third,
fourth or even fifth line therapy is difficult. Previous trials
of chemotherapy in recurrent ovarian cancer have docu-
mented response rates between 13–50% and this includes
trials of second-line therapy and patients with stage I and
II disease [28–35] There are few randomised trials and
none have demonstrated a clear benefit for one regimen
over another. Clinical activity has been demonstrated
with agents such as pegylated liposomal doxorubicin
[29,33], topotecan [28,30,32], altretamine [34], gemcit-
abine [36] and etoposide [37]. The heterogeneity of
response to treatment in recurrent ovarian cancer makes
choice of treatment difficult.
Table 3: Results of chemotherapy
No. of patients 46
No. ATP-TCA directed courses 56
CR 12 (21%)
PR 21 (38%)
SD 6 (11%)
PD 15 (27%)
No. of patients not evaluable for response 2 (4%)
ORR 33 (59%)
Median PFS (months) 6.6
Median OAS (months) 10.4BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/19
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There are no data conclusively proving combination ther-
apy is superior to single-agent therapy in relapsed disease.
Increased activity with some combinations has been
shown in randomised trials, but often in selected groups
and it is not certain that the benefit will translate into
improved survival [38]. Two studies have recently shown
impressive response rates using weekly cisplatin and oral
etoposide [9,10]. Van der Burg et al. [10] used a different
definition of platinum sensitivity to Meyer et al. [9],
favouring the 1998 consensus classification [39]. This
grouped patients into platinum refractory, platinum inter-
mediate-sensitive and platinum sensitive based on their
treatment free interval since last platinum containing
therapy (i.e. <4 months, 4–12 months and >12 months,
respectively). The response rates were 46%, 91% and 92%
in the refractory, intermediate and sensitive groups respec-
tively. However, the patient sample differed considerably
from ours in that 90% of the patient sample had a WHO
performance status of 0 or 1 and 74% had only one prior
chemotherapy regimen. Survival was not calculated on an
intention to treat analysis. We believe our group of
patients is more representative of the everyday clinic situ-
ation, were of a poorer prognostic group (median WHO
performance status of 2 and 80% of patients with ascites),
and have shown benefit from the use of the ATP-TCA.
Meyer et al. [9] used a relapse cut-off of six months to
define platinum sensitive patients. Using CA125 criteria
to assess response they found that 46% of platinum resist-
ant patients responded to this regimen (median survival
6.3 months). The response rate in the platinum sensitive
group was slightly less (43%). This is surprising and very
different from the results published by van der Burg et al.
[10] We used the same definition of platinum sensitivity
as Meyer et al. [9] and have also seen a similar ORR (61%
and 65% for platinum resistant and platinum sensitive
PFS following assay-directed chemotherapy Figure 1
PFS following assay-directed chemotherapy.
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patients respectively) between the two groups. However,
when grouped by Index SUM for cisplatin the differences
are more marked (58% and 75% ORR for Index SUM
>350 and <350 for cisplatin respectively). The majority of
patients treated by Meyer et al. [9] had 2 or more prior
courses of chemotherapy which is similar to our own fig-
ures (72% two or more prior chemotherapy courses).
When analysed on an ITT basis the series treated by Meyer
et al. [9] have an ORR of 36%, a PFS of 3.7 months and an
OAS of 6.6 months. Our group have shown a greater
response rate and longer median survival times (ORR
59%, PFS 6.6 months, OAS 10.4 months).
At first sight, the clinical definition of platinum resistance
does not appear to match the number of patients showing
cisplatin resistance on the basis of Index SUM in the ATP-
TCA. However, most patients in this study had been
rechallenged with a second line platinum agent/combina-
tion and the assay taken before third-line therapy (or
later) shows the expected increase in the cisplatin Index
SUM due to acquired resistance. By the time patients pre-
sented for ATP-TCA directed therapy 72% were platinum
resistant according to the assay (cisplatin Index
SUM>350). Previous studies have shown a negative pre-
dictive value of the order of 90% for resistance to cisplatin
in the assay [16].
Most patients in this study were treated with combination
therapy, often with experimental protocols. These combi-
nations were previously developed on the basis of assay
results and have known clinical efficacy [40,41]. Those
chosen for individual patients often differed due to the
wide heterogeneity of chemosensitivity exhibited in ovar-
ian epithelial cancer [13,14,16]. The ATP-TCA not infre-
quently suggests potential benefit from drug regimens
that may be far from the physician's first choice. Treosul-
OAS following assay-directed chemotherapy Figure 2
OAS following assay-directed chemotherapy.
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fan + gemcitabine is a new regimen with a good toxicity
profile, initially developed for melanoma [42,43], which
has been shown to have considerable activity against ovar-
ian cancer in a recent study [44,45]. In this series, treosul-
fan and gemcitabine was used 23 times (41%) and
achieved an ORR of 55%. Of patients evaluable for
response, thirteen patients receiving this combination
were resistant to cisplatin in the assay (cisplatin Index
SUM > 350) and the ORR in this group was 62%. Six
patients were predicted as platinum-sensitive (cisplatin
Index SUM < 350), and half of these responded to treosul-
fan and gemcitabine. The remaining three patients
received treosulfan and gemcitabine, but cisplatin was not
tested in the assay. Other combinations used in the assay
varied widely in their mechanism of action: many
involved anthracyclines and some used paclitaxel (Table
2). There was reluctance amongst the oncologists involved
in this study to re-use paclitaxel, though recent results
with the ATP-TCA suggest that resistance to this agent
develops less commonly than to platinum [40]. Kaern et
al. [46] studied taxane rechallenge after platinum/paclit-
axel therapy and found that the likelihood to respond to
second-line paclitaxel is largely unaffected by the prior
progression free interval.
Figure 3 shows a profile of the CA-125 levels of a patient
treated with 3 successive courses of assay directed therapy.
This patient was clinically platinum resistant after having
been treated with CAP (cyclophosphamide, doxorubicin
and cisplatin) four months prior to the start time point of
the graph. Sequential ATP-TCA assays recommended cis-
platin and gemcitabine; Liposomal doxorubicin; Mitox-
antrone and paclitaxel respectively. The arrows show
when each treatment was started. These achieved 3
sequential partial responses in the patient with significant
drops in the CA-125 counts. A fourth assay recommended
CA-125 profile for a patient with 3 successive courses of assay directed therapy Figure 3
CA-125 profile for a patient with 3 successive courses of assay directed therapy
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treosulfan and gemcitabine, but the patient deteriorated
rapidly after 2 cycles and died soon after. Nevertheless,
this patient survived 18 months after diagnosis of plati-
num-resistant recurrent ovarian cancer. This example
shows how the assay can be use to assist the choice of
chemotherapy on multiple occasions during the course of
an individual patient's illness.
The use of predictive assays to individualize chemother-
apy has been hampered by technical difficulties and (ini-
tially) by the availability of drugs with differing
mechanisms of action. The increasing number of drugs
now available has widened the choice of agents and pos-
sible combinations considerably. The ATP-TCA is a well-
standardised assay with established external quality con-
trol procedures capable of handling most endoscopic or
needle biopsies that compares favourably with other clo-
nogenic and non-clonogenic methods [13,14,47,48].
Conclusions
In conclusion, the ATP-TCA assay shows favourable
response rates when used as a predictive assay to individ-
ualize chemotherapy in heavily pre-treated recurrent epi-
thelial ovarian cancer. These results compare well with
published second-line therapy results and support previ-
ous work using the ATP-TCA in a different country. A
multi-centre, randomised trial of ATP-TCA directed ther-
apy versus physician's choice therapy is in progress to help
clarify the role of predictive chemosensitivity testing in
recurrent ovarian cancer.
Competing Interests
This work was supported by grants from Schering-Plough
(UK) Ltd, Xenova Ltd, Cantech Ltd, the Biology and Bio-
technology Science Research Council, and the European
Commission. IAC is a director of Cantech Ltd.
Authors' Contributions
SS completed clinical follow-up and drafted the manu-
script. MHN, FDN, LAK, PAW, SJM carried out the ATP-
TCA assays. BRH provided statistical input. AL, RO, ACH
recruited and treated patients. CMK and IAC conceived
the study and participated in its design and coordination.
Acknowledgements
We are indebted to Amanda Brookman at King Edward VII Hospital, Mid-
hurst and the Wellcome Trust International Travel Award Scheme. We 
also thank Peggy Hurworth, Marilyn Phillips, Claire Balmer and Natalie Tidy 
for their assistance with data collection.
References
1. Greenlee Robert T., Hill-Harmon Mary Beth, Murray Taylor and
Thun Michael: Cancer Statistics, 2001 CA Cancer J Clin 2001, 51:15-
36.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look
KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and
cisplatin compared with paclitaxel and cisplatin in patients
with stage III and stage IV ovarian cancer N Engl J Med 1996,
334:1-6.
3. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E,
Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swen-
erton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA,
Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron
B and Pecorelli S: Randomized intergroup trial of cisplatin-
paclitaxel versus cisplatin-cyclophosphamide in women with
advanced epithelial ovarian cancer: three-year results J Natl
Cancer Inst 2000, 92:699-708.
4. Gore ME, Fryatt I, Wiltshaw E and Dawson T: Treatment of
relapsed carcinoma of the ovary with cisplatin or carboplatin
following initial treatment with these compounds  Gynecol
Oncol 1990, 36:207-211.
5. Thigpen JT, Blessing JA, Ball H, Hummel SJ and Barrett RJ: Phase II
trial of paclitaxel in patients with progressive ovarian carci-
noma after platinum-based chemotherapy: a Gynecologic
Oncology Group study J Clin Oncol 1994, 12:1748-1753.
6. Blackledge G, Lawton F, Redman C and Kelly K: Response of
patients in phase II studies of chemotherapy in ovarian can-
cer: implications for patient treatment and the design of
phase II trials Br J Cancer 1989, 59:650-653.
7. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S,
Jones W, Almadrones L and Lewis J. L., Jr.: Second-line platinum
therapy in patients with ovarian cancer previously treated
with cisplatin J Clin Oncol 1991, 9:389-393.
8. Gore Martin: Treatment of relapsed epithelial ovarian cancer
American Society of Clinical Oncology: 2001 Educational Book Edited by:
Michael C Perry. Alexandria VA, American Society of Clinical Oncology;
2001:468-476.
9. Meyer T, Nelstrop AE, Mahmoudi M and Rustin GJ: Weekly cispla-
tin and oral etoposide as treatment for relapsed epithelial
ovarian cancer Ann Oncol 2001, 12:1705-1709.
10. van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH,
Stoter G and Verweij J: Weekly cisplatin and daily oral etopo-
side is highly effective in platinum pretreated ovarian cancer
Br J Cancer 2002, 86:19-25.
11. Von Hoff DD, Sandbach JF, Clark GM, Turner JN, Forseth BF, Piccart
MJ, Colombo N and Muggia FM: Selection of cancer chemother-
apy for a patient by an in vitro assay versus a clinician J Natl
Cancer Inst 1990, 82:110-116.
12. Von Hoff DD, Kronmal R, Salmon SE, Turner J, Green JB, Bonorris JS,
Moorhead EL, Hynes HE, Pugh RE, Belt RJ and et al.: A Southwest
Oncology Group study on the use of a human tumor cloning
assay for predicting response in patients with ovarian cancer
Cancer 1991, 67:20-27.
13. Cree IA and Kurbacher CM: Individualizing chemotherapy for
solid tumors--is there any alternative? Anticancer Drugs 1997,
8:541-548.
14. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D,
Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M and et al.:
Chemosensitivity testing of human tumors using a micro-
plate adenosine triphosphate luminescence assay: clinical
correlation for cisplatin resistance of ovarian carcinoma Can-
cer Res 1995, 55:5276-5282.
15. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi
AM, James EA, Dewar JA, Preece PE, Andreotti PE and Bruckner HW:
Correlation of the clinical response to chemotherapy in
breast cancer with ex vivo chemosensitivity Anticancer Drugs
1996, 7:630-635.
16. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C,
Cree IA, Hepp H and Untch M: Correlation of drug response
with the ATP tumorchemosensitivity assay in primary FIGO
stage III ovarian cancer Gynecol Oncol 2000, 77:258-263.
17. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA,
Muller K, Ackermann T, Gilster TJ, Wilhelm LM, Engel H, Mallmann
PK and Andreotti PE: Use of an ex vivo ATP luminescence assay
to direct chemotherapy for recurrent ovarian cancer Antican-
cer Drugs 1998, 9:51-57.
18. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins
WJ, Mitchell H and Lambert HE: Defining response of ovarian
carcinoma to initial chemotherapy according to serum CA
125 J Clin Oncol 1996, 14:1545-1551.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubin-
stein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC
and Gwyther SG: New guidelines to evaluate the response toPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/19
Page 10 of 10
(page number not for citation purposes)
treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Insti-
tute of the United States, National Cancer Institute of
Canada J Natl Cancer Inst 2000, 92:205-216.
20. Markman M and Hoskins W: Responses to salvage chemother-
apy in ovarian cancer: a critical need for precise definitions
of the treated population J Clin Oncol 1992, 10:513-514.
21. Markman M: "Recurrence within 6 months of platinum ther-
apy": an adequate definition of "platinum-refractory" ovar-
ian cancer? Gynecol Oncol 1998, 69:91-92.
22. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Wood RA,
Linder D and Andreotti PE: Heterogeneity of chemosensitivity
in human breast carcinoma: use of an adenosine triphos-
phate (ATP) chemiluminescence assay Eur J Surg Oncol 1993,
19:242-249.
23. du Bois A: Treatment of advanced ovarian cancer Eur J Cancer
2001, 37:S1-7.
24. Ettinger DS, Finkelstein DM, Abeloff MD, Skeel RT, Stott PB, Fron-
tiera MS and Bonomi PD: Justification for evaluating new anti-
cancer drugs in selected untreated patients with extensive-
stage small-cell lung cancer: an Eastern Cooperative Oncol-
ogy Group randomized study J Natl Cancer Inst 1992, 84:1077-
1084.
25. Markman M, Kennedy A, Webster K, Kulp B, Peterson G and Belin-
son J: Continued chemosensitivity to cisplatin/carboplatin in
ovarian carcinoma despite treatment with multiple prior
platinum-based regimens Gynecol Oncol 1997, 65:434-436.
26. Breidenbach M, Rein DT, Mallmann P and Kurbacher CM: Individu-
alized long-term chemotherapy for recurrent ovarian can-
cer after failing high-dose treatment  Anticancer Drugs 2002,
13:173-176.
27. Donovan KA, Greene PG, Shuster JL, Partridge EE and Tucker DC:
Treatment preferences in recurrent ovarian cancer Gynecol
Oncol 2002, 86:200-211.
28. Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kris-
tensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte
MH and Fields SZ: Oral topotecan as single-agent second-line
chemotherapy in patients with advanced ovarian cancer J Clin
Oncol 2001, 19:3967-3975.
29. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME and Lacave
AJ: Recurrent epithelial ovarian carcinoma: a randomized
phase III study of pegylated liposomal doxorubicin versus
topotecan J Clin Oncol 2001, 19:3312-3322.
30. Gore M, Oza A, Rustin G, Malfetano J, Calvert H, Clarke-Pearson D,
Carmichael J, Ross G, Beckman RA and Fields SZ: A randomised
trial of oral versus intravenous topotecan in patients with
relapsed epithelial ovarian cancer Eur J Cancer 2002, 38:57-63.
31. Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H and Thomp-
son JM: Paclitaxel (Taxol) in relapsed and refractory ovarian
cancer: the UK and Eire experience Br J Cancer 1995, 72:1016-
1019.
32. Hanjani P, Nolte S and Shahin MS: Phase II evaluation of 3-day
topotecan with cyclophosphamide in the treatment of recur-
rent ovarian cancer Gynecol Oncol 2002, 85:278-284.
33. Hensley ML, Hoppe B, Leon L, Sabbatini P, Aghajanian C, Chi D and
Spriggs DR: The costs and efficacy of liposomal doxorubicin in
platinum-refractory ovarian cancer in heavily pretreated
patients Gynecol Oncol 2001, 82:464-469.
34. Rustin GJ, Nelstrop AE, Crawford M, Ledermann J, Lambert HE,
Coleman R, Johnson J, Evans H, Brown S and Oster W: Phase II trial
of oral altretamine for relapsed ovarian carcinoma:
evaluation of defining response by serum CA125 J Clin Oncol
1997, 15:172-176.
35. Villa A, Parazzini F, Scarfone G, Guarnerio P and Bolis G: Survival
and determinants of response to third-line chemotherapy in
sensitive recurrent ovarian cancer patients Br J Cancer 1999,
79:373-374.
36. Lund B, Hansen OP, Theilade K, Hansen M and Neijt JP: Phase II
study of gemcitabine (2',2'-difluorodeoxycytidine) in previ-
ously treated ovarian cancer patients J Natl Cancer Inst 1994,
86:1530-1533.
37. Rose PG, Blessing JA, Mayer AR and Homesley HD: Prolonged oral
etoposide as second-line therapy for platinum-resistant and
platinum-sensitive ovarian carcinoma: a Gynecologic Oncol-
ogy Group study J Clin Oncol 1998, 16:405-410.
38. Harries M and Gore M: Part II: chemotherapy for epithelial
ovarian cancer-treatment of recurrent disease Lancet Oncol
2002, 3:537-545.
39. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer
EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Hor-
vath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF,
Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin
GJ, Sessa C, Willemse PH and et al.: Advanced epithelial ovarian
cancer: 1998 consensus statements Ann Oncol 1999, 10:87-92.
40. Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L,
Poch G, Indefrei D, Mallmann P and Andreotti PE: Mitoxantrone
combined with paclitaxel as salvage therapy for platinum-
refractory ovarian cancer: laboratory study and clinical pilot
trial Clin Cancer Res 1997, 3:1527-1533.
41. Kurbacher CM Stier U, Janat M, Cree IA, Bruckner HW: ATP-assay
directed chemotherapy for recurrent ovarian cancer:
Mature results of an ISCO clinical study group trial ASCO Vol-
ume 20. Edited by: Steven M Grunberg. San Francisco, CA, American Soci-
ety of Clinical Oncology; 2001184b.
42. Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL and Plow-
man PN: The ex vivo chemosensitivity profile of choroidal
melanoma Anticancer Drugs 1997, 8:756-762.
43. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL
and Plowman PN: Combination chemotherapy for choroidal
melanoma: ex vivo sensitivity to treosulfan with gemcitabine
or cytosine arabinoside Br J Cancer 1999, 79:1487-1493.
44. Breidenbach M Rein D, Konig P, Bruckner HW, Kurbacher CM: Tox-
icity profiles of different chemotherapy regimens for recur-
rent ovarian cancer guided by an ex vivo chemosensitivity
assay ASCO Volume 20. Edited by: Steven M Grunberg. San Francisco,
CA, American Society of Clinical Oncology; 2001181b.
45. Grecu OM Kurbacher CM, Mallmann P, Bruckner HW, Cree IA: Tre-
osulfan and gemcitabine in heavily pretreated patients with
breast and ovarian cancer: Laboratory study and clinical
pilot trial of the ISCO clinical study group ASCO Volume 20.
Edited by: Steven M Grunberg. San Francisco, CA, American Society of Clin-
ical Oncology; 2001187b.
46. Kaern J Trope CG, Baekelandt M, Kristensen GB: Phase II trial of
weekly single agent paclitaxel (P) in platinum (PLAT) and
paclitaxel refractory ovarian cancer (OC)  ASCO  Volume 20.
Edited by: Steven M Grunberg. San Francisco, CA, American Society of Clin-
ical Oncology; 2001203a.
47. Cree IA, Pazzagli M, Mini E, Mazzei T, Hunter EM, Sutherland LA, Pin-
zani P, Gerli A and Andreotti PE: Methotrexate chemosensitivity
by ATP luminescence in human leukemia cell lines and in
breast cancer primary cultures: comparison of the TCA-100
assay with a clonogenic assay Anticancer Drugs 1995, 6:398-404.
48. Petty RD, Sutherland LA, Hunter EM and Cree IA: Comparison of
MTT and ATP-based assays for the measurement of viable
cell number J Biolumin Chemilumin 1995, 10:29-34.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/3/19/prepub